The EPS projection of Core Laboratories N.V. (NYSE:CLB) for quarter ended 2016-09-30 is $0.37. Last week, the projection for EPS was $0.37 against target of $0.37, a month earlier. While 2-months ago, this projection was $0.37 versus forecast of $0.37a quarter months earlier, posting a deviation of 0%.
Core Laboratories N.V. (NYSE:CLB) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 2.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 0, and 1, correspondingly.
The per-share earnings downgrade for Core Laboratories N.V. (NYSE:CLB) in the preceding 30 and 120 were 0 and 3. While in 60 and 90 days were 1, and 2, in that order.
Core Laboratories N.V. (NYSE:CLB) EPS target was $0.37 for the quarter closed 1. It was based on 5 calls. As on 2016-04-20 the EPS was $0.37. The change was $0, posting a deviation of 0%. The price projections gave a standard deviation of 0.02.
Quarterly Sales Estimates
Core Laboratories N.V. (NYSE:CLB) sales prediction for the fiscal 2017 stands at $160.1 and the median estimate is at $160.1. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $161.6 while the lowest target is $158.6 showing standard deviation of 2.121%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of 0%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of 1.586%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...